KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Change in Inventory (2017 - 2025)

BeOne Medicines (ONC) has disclosed Change in Inventory for 9 consecutive years, with $70.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Inventory fell 11.18% to $70.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $93.2 million, a 1.83% increase, with the full-year FY2025 number at $93.2 million, up 1.83% from a year prior.
  • Change in Inventory was $70.5 million for Q4 2025 at BeOne Medicines, up from $28.8 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $91.6 million in Q4 2021 to a low of -$23.8 million in Q3 2024.
  • A 5-year average of $26.8 million and a median of $28.7 million in 2022 define the central range for Change in Inventory.
  • Biggest YoY gain for Change in Inventory was 1357.53% in 2021; the steepest drop was 7450.9% in 2021.
  • BeOne Medicines' Change in Inventory stood at $91.6 million in 2021, then crashed by 120.67% to -$18.9 million in 2022, then soared by 567.6% to $88.6 million in 2023, then decreased by 10.38% to $79.4 million in 2024, then dropped by 11.18% to $70.5 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Change in Inventory are $70.5 million (Q4 2025), $28.8 million (Q3 2025), and -$2.2 million (Q2 2025).